keyword
MENU ▼
Read by QxMD icon Read
search

Dotation

keyword
https://www.readbyqxmd.com/read/29155309/prognostic-utility-of-total-68-ga-dotatate-avid-tumor-volume-in-patients-with-neuroendocrine-tumors
#1
Amit Tirosh, Georgios Z Papadakis, Corina Millo, Dima Hammoud, Samira M Sadowski, Peter Herscovitch, Karel Pacak, Stephen J Marx, Lily Yang, Pavel Nockel, Jasmine Shell, Patience Green, Xavier M Keutgen, Dhaval Patel, Naris Nilubol, Electron Kebebew
BACKGROUND & AIMS: Survival times vary among patients with neuroendocrine tumors (NETs)-even among those with the same site, stage, and grade of primary tumor. This makes it difficult to select treatment for patients with unresectable NETs, because some patients can survive decades without treatment. (68)Gallium-DOTATATE positron emission tomography with computed tomography ((68)Ga-DOTATATE PET/CT) is a sensitive imaging technique for detection of NETs. We investigated the prognostic accuracy of (68)Ga-DOTATATE PET/CT analysis of tumor volume in patients with NETs...
November 16, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29149420/blood-clearance-and-occupational-exposure-for-177-lu-dotatate-compared-to-177-lu-psma-radionuclide-therapy
#2
Mohammad Abuqbeitah, Mustafa Demir, Lebriz Uslu-Beşli, Nami Yeyin, Kerim Sönmezoğlu
The main target of this work is to examine blood clearance and external exposure for (177)Lu-DOTATATE compared with new emerging (177)Lu-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 ± 1.1 GBq (177)Lu-DOTATATE were compared to those of 23 patients treated with 7.4 GBq (177)Lu-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters...
November 17, 2017: Radiation and Environmental Biophysics
https://www.readbyqxmd.com/read/29144820/pheochromocytoma-a-genetic-and-diagnostic-update
#3
Leilani B Mercado-Asis, Katherine I Wolf, Ivana Jochmanova, David Taïeb
OBJECTIVE: Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors derived from adrenal or extra-adrenal locations, respectively. Upon suspicion of PPGL, specific metabolomic, molecular, biochemical, imaging, and histopathological studies are performed to prove, localize, treat, and monitor disease progression. Recently, improved diagnostic tools allow physicians to accurately diagnose PPGL, even in patients presenting with small (less than 1 cm) or biochemically silent tumors, which previously delayed proper detection and treatment...
November 16, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29135613/68ga-dotatate-uptake-in-ischemic-stroke
#4
Émilie Vallée, Nancy Paquet, James Patrick Buteau, Éric Turcotte
A 76-year-old man known to have a pancreatic neuroendocrine tumor with hepatic and lymph nodes metastasis had a follow-up Ga-DOTATATE PET/CT before Lu-DOTATATE therapy. A new cerebral lesion expressing somatostatin receptors was discovered in the right temporal lobe, suggestive of an ischemic stroke territory. This was later confirmed from the hospital chart where an ischemic stroke was described a month ago.
November 11, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29125780/segmentation-of-whole-body-images-into-two-compartments-in-model-for-bone-marrow-dosimetry-increases-the-correlation-with-hematological-response-in-177-lu-dotatate-treatments
#5
Linn Hagmarker, Johanna Svensson, Tobias Rydén, Peter Gjertsson, Peter Bernhardt
BACKGROUND: In (177)Lu-DOTATATE treatments, bone marrow (BM) is one of the most important organs at risk. The authors previously developed an image-based two-compartment method for BM dosimetry, showing a significant correlation between absorbed dose to BM and hematological toxicity in (177)Lu-DOTATATE treatments. In the present study, they aimed to further evaluate this BM dosimetry method by finding optimal settings for dividing the whole body into two compartments; in terms of minimizing the coefficient of variation (CV) for the individual absorbed doses and studying its correlation to the BM response...
November 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/29107992/software-assisted-dosimetry-in-peptide-receptor-radionuclide-therapy-with-177lutetium-dotatate-for-various-imaging-scenarios
#6
Dennis Kupitz, Christoph Wetz, Heiko Wissel, Florian Wedel, Ivayla Apostolova, Thekla Wallbaum, Jens Ricke, Holger Amthauer, Oliver S Grosser
In peptide receptor radionuclide therapy (PRRT) of patients with neuroendocrine neoplasias (NENs), intratherapeutic dosimetry is mandatory for organs at risk (e.g. kidneys) and tumours. We evaluated commercial dosimetry software (Dosimetry Toolkit) using varying imaging scenarios, based on planar and/or tomographic data, regarding the differences in calculated organ/tumour doses and the use for clinical routines. A total of 16 consecutive patients with NENs treated by PRRT with 177Lu-DOTATATE were retrospectively analysed...
2017: PloS One
https://www.readbyqxmd.com/read/29076916/68ga-dotatate-uptake-in-a-soft-tissue-metastasis-from-clear-cell-renal-cell-cancer
#7
S Vamadevan, K Le, L Shen, A Stevanovic, H Loh, R Mansberg
A 64-year-old man with a history of metastatic clear cell renal cell cancer was referred for progress Ga-DOTATATE PET/CT imaging. Ga-DOTATATE PET/CT imaging demonstrated increased DOTATATE uptake (SUVmax 13.8) in the left thigh localized to a soft tissue lesion. Cytopathology of the resected lesion was in keeping with a clear cell renal cell cancer metastasis. This case illustrates that Ga-DOTATATE accumulation in a soft tissue lesion can be due to a clear cell renal cell cancer metastasis.
October 26, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29076910/optimizing-somatostatin-receptor-imaging-in-patients-with-neuroendocrine-tumors-the-impact-of-99mtc-hynictoc-spect-spect-ct-versus-68ga-dotatate-pet-ct-upon-clinical-management
#8
Jolanta Kunikowska, Valerie Lewington, Leszek Krolicki
AIM: The presence of somatostatin receptors in neuroendocrine tumors allows visualization with radiolabeled somatostatin analogs in vivo. The aim of this prospective study was to compare somatostatin receptor imaging using Tc-HYNICTOC with Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) with respect to sensitivity, specificity, and impact upon clinical decision making. METHODS: Sixty-eight patients (30 men, 38 women; aged 56.4 ± 13.5 years) with disseminated, histologically proven neuroendocrine tumor were enrolled...
December 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29072093/the-utility-of-68-ga-dotatate-positron-emission-tomography-computed-tomography-in-the-diagnosis-management-follow-up-and-prognosis-of-neuroendocrine-tumors
#9
Amit Tirosh, Electron Kebebew
Neuroendocrine tumors (NETs) are rare neoplasms that emerge mainly from the GI tract, pancreas and respiratory tract. The incidence of NETs has increased more than sixfold in the last decades. NETs typically express somatostatin receptors on their cell surface, which can be targeted by 'cold' somatostatin analogs for therapy or by 'hot' radiolabeled somatostatin analogs for tumor localization and treatment. 68-Gallium-DOTA peptides (DOTATATE, DOTATOC, DOTANOC) positron emission tomography/computed tomography is a highly accurate imaging modality for NETs that has been found to be more sensitive for NET detection than other imaging modalities...
October 26, 2017: Future Oncology
https://www.readbyqxmd.com/read/29043399/immunohistochemical-evaluation-of-molecular-radiotherapy-target-expression-in-neuroblastoma-tissue
#10
Jennifer E Gains, Neil J Sebire, Veronica Moroz, Keith Wheatley, Mark N Gaze
PURPOSE: Neuroblastoma may be treated with molecular radiotherapy, (131)I meta-Iodobenzylguanidine and (177)Lu Lutetium DOTATATE, directed at distinct molecular targets: Noradrenaline Transporter Molecule (NAT) and Somatostatin Receptor (SSTR2), respectively. This study used immunohistochemistry to evaluate target expression in archival neuroblastoma tissue, to determine whether it might facilitate clinical use of molecular radiotherapy. METHODS: Tissue bank samples of formalin fixed paraffin embedded neuroblastoma tissue from patients for whom clinical outcome data were available were sectioned and stained with haematoxylin and eosin, and monoclonal antibodies directed against NAT and SSTR2...
October 17, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28963390/acromegaly-with-hypophosphataemia-mccune-albright-syndrome
#11
Rimesh Pal, Pinaki Dutta, Kanchan Kumar Mukherjee, Anil Bhansali
A 38-year-old man presented with excessive height gain and progressive enlargement of the extremities since childhood. This was compounded by lower limb deformities over the past 5 years. On examination, his height was 196 cm, he had macroglossia, acral enlargement, seborrhoea, hyperhidrosis-suggesting acrogigantism. He had facial asymmetry, wind-swept deformity of lower limbs and a café-au-lait macule over his trunk. Investigations revealed normal-sized pituitary gland with dysplastic cranial bones. Isotope bone scintigraphy was suggestive of polyostotic fibrous dysplasia...
September 28, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28920501/kidney-dosimetry-during-177-lu-dotatate-therapy-in-patients-with-neuroendocrine-tumors-aspects-on-calculation-and-tolerance
#12
Mattias Sandström, Ulrike Garske-Román, Silvia Johansson, Dan Granberg, Anders Sundin, Nanette Freedman
BACKGROUND: Fractionated therapy with (177)Lu-DOTATATE has been reported to be an effective treatment for patients with metastasized neuroendocrine tumors. To optimize the treatment, absorbed doses to risk organs are calculated for the individual patient. For each organ, absorbed dose due to activity in the organ itself (self-dose) and that originating from other organs (cross-dose) are calculated from serial measurements to obtain the activity distribution following treatment. The main aim of the present work were to calculate the cross-dose contribution to the total absorbed kidney dose...
September 18, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28890865/functional-imaging-of-paragangliomas-with-an-emphasis-on-von-hippel-lindau-associated-disease-a-mini-review
#13
REVIEW
Ioannis Ilias, Georgios Meristoudis
Few reports have presented data and results on functional (i.e., nuclear medicine) imaging of paragangliomas and pheochromocytomas (PGLs/PHEOs) for von Hippel-Lindau (VHL) patients. Nuclear medicine localization modalities for chromaffin tumors can be specific or nonspecific. Specific methods make use of the expression of the human norepinephrine transporter (hNET) and vesicular monoamine transporters (VMATs) by these tumors. These permit the use of radiolabeled ligands that enter the synthesis and storage pathway of catecholamines...
2017: Journal of Kidney Cancer and VHL
https://www.readbyqxmd.com/read/28872545/concomitant-177lu-dotatate-and-capecitabine-therapy-in-patients-with-advanced-neuroendocrine-tumors-a-long-term-outcome-toxicity-survival-and-quality-of-life-study
#14
Sanjana Ballal, Madhav P Yadav, Nishikant A Damle, Ranjit K Sahoo, Chandrasekhar Bal
PURPOSE: The purpose of this study was to evaluate the outcome, toxicity, survival, and quality of life in patients with advanced neuroendocrine tumors. METHODS: One hundred sixty-seven patients were enrolled in the study. All patients underwent baseline Ga-DOTANOC PET/CT scans. Lu-DOTATATE therapy was administered quarterly along with oral capecitabine therapy in group 1 patients (n = 88), whereas group 2 patients (n = 79) were treated only with Lu-DOTATATE. Hematologic, kidney function, liver function tests and chromogranin A levels were recorded before and after therapy at 2-week, 4-week, and 3-month intervals...
September 1, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28864614/somatostatin-receptor-antagonists-for-imaging-and-therapy
#15
REVIEW
Melpomeni Fani, Guillaume P Nicolas, Damian Wild
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An important improvement in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [(90)Y-DOTA(0),Tyr(3)]octreotide or [(177)Lu-DOTA(0),Tyr(3)]octreotide ((90)Y- or (177)Lu-DOTATOC, respectively) and [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE). PET/CT with (68)Ga-labeled sstr agonists, such as (68)Ga-DOTATOC, (68)Ga-DOTATATE, and [(68)Ga-DOTA,1-Nal(3)]octreotide ((68)Ga-DOTANOC), plays an important role in staging and restaging neuroendocrine tumors...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28840066/pituitary-carcinoma-a-case-report-and-discussion-of-potential-value-of-combined-use-of-ga-68-dotatate-and-f-18-fdg-pet-ct-scan-to-better-choose-therapy
#16
Heraldo Mendes Garmes, José Barreto Campello Carvalheira, Fabiano Reis, Luciano de Souza Queiroz, Mateus Dal Fabbro, Vanessa de Fatima Porto Souza, Allan de Oliviera Santos
BACKGROUND: Pituitary carcinoma is extremely rare and carries a very poor prognosis. In most cases, apparently indolent tumors become malignant; however, there are no satisfactory biomarkers for predicting tumor behavior. Thus, scientific advances in the search for new biological markers, diagnostic methods, and therapies are needed to improve the prognosis of these patients. CASE DESCRIPTION: We report the case of a woman with initial diagnosis of nonfunctioning pituitary adenoma which evolved to carcinoma after 4 years...
2017: Surgical Neurology International
https://www.readbyqxmd.com/read/28832377/safety-and-effectiveness-of-177lu-dotatate-peptide-receptor-radionuclide-therapy-after-regional-hepatic-embolization-in-patients-with-somatostatin-expressing-neuroendocrine-tumors
#17
Mohammadali Hamiditabar, Muzammil Ali, Luke Bolek, Gelareh Vahdati, Izabela Tworowska, Ebrahim S Delpassand
PURPOSE: Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE is shown to be an effective therapeutic option for somatostatin-expressing neuroendocrine neoplasms. Some concerns are raised over safety of this modality in patients with a history of regional chemoembolization and radionuclide hepatic embolization (CRHE) and is cause of reluctance among some physicians for suggesting Lu-DOTATATE in this patient population. METHODS: We retrospectively reviewed 143 patients with somatostatin-expressing neuroendocrine tumors who underwent Lu-DOTATATE PRRT...
November 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28818983/current-concepts-in-68-ga-dotatate-nen-imaging-interpretation-biodistribution-dosimetry-and-molecular-strategies
#18
Lisa Bodei, Valentina Ambrosini, Ken Herrmann, Irvin Modlin
(68)Ga-DOTATATE PET/CT provides information of the location(s) of somatostatin receptor expressing tumors. Integrating this imaging data effectively in patient care requires the clinical history, the histopathology and biomarker information as well as grade, stage and prior imaging. Previous therapies and technical aspects of the study should be considered, given their ability to alter the interpretation of the images. This includes physiologic biodistribution of the radiotracer, as well as conditions that engender false positive results...
August 17, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28806249/epidural-metastases-from-follicular-thyroid-cancer-mimicking-meningiomas-in-68ga-dotatate-pet
#19
Marcus Unterrainer, Harun Ilhan, Andrei Todica, Peter Bartenstein, Nathalie Lisa Albert
We report a woman with multifocal lesions suggestive of meningiomas in MRI, which also presented with high Ga-DOTATATE uptake in PET, a finding characteristic for meningioma. A whole-body staging due to a pathological fracture revealed multiple neoplastic lesions throughout the body without detection of a primary site. Subsequent pathological workup of a lung lesion revealed multifocal metastases from follicular thyroid cancer despite thyroidectomy 10 years ago (without pathological finding), and posttreatment scans after radioiodine therapy confirmed the multiple brain lesions to be metastases as well...
October 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28798227/-68-ga-dotatate-pet-ct-can-be-an-alternative-imaging-method-in-insulinoma-patients
#20
Sadiye Altun Tuzcu, Zafer Pekkolay, Faruk Kılınç, Alpaslan Kemal Tuzcu
Insulinomas are the most common cause of hypoglycemia, resulting from endogenous hyperinsulinism. The diagnosis of insulinoma is established by demonstrating inappropriately high serum insulin concentrations during a spontaneous or induced episode of hypoglycemia. Most insulinomas are islet-cell tumors. They are often small (<2 cm), benign, and difficult to localize with current imaging techniques. Insulinomas can be detected using either noninvasive procedures (e.g., transabdominal ultrasonography, spiral CT, MRI, (111)In-pentetreotide imaging, and (18)F-l-dihydroxyphenylalanine PET) or invasive procedures (e...
September 2017: Journal of Nuclear Medicine Technology
keyword
keyword
96892
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"